Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery
Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concen...
Saved in:
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2022
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/160960 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-160960 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1609602022-08-08T08:30:03Z Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery Paul, Mahasweta Lau, Raymond School of Chemical and Biomedical Engineering Engineering::Bioengineering Particle Characterization Inhalation Drug Delivery Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations. 2022-08-08T08:30:03Z 2022-08-08T08:30:03Z 2020 Journal Article Paul, M. & Lau, R. (2020). Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery. Advanced Powder Technology, 31(6), 2357-2365. https://dx.doi.org/10.1016/j.apt.2020.03.028 0921-8831 https://hdl.handle.net/10356/160960 10.1016/j.apt.2020.03.028 2-s2.0-85083305054 6 31 2357 2365 en Advanced Powder Technology © 2020 The Society of Powder Technology Japan. All rights reserved. |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Engineering::Bioengineering Particle Characterization Inhalation Drug Delivery |
spellingShingle |
Engineering::Bioengineering Particle Characterization Inhalation Drug Delivery Paul, Mahasweta Lau, Raymond Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery |
description |
Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson's disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater drug bioavailability, increased blood plasma concentrations for longer periods and the ability to bypass the blood brain barrier. This review aims to highlight and summarize the recent advances made in the development of Levodopa particle formulations in terms of its characteristics, production techniques, choice of carrier materials, as well as pharmacokinetics and pharmacodynamics the formulations. |
author2 |
School of Chemical and Biomedical Engineering |
author_facet |
School of Chemical and Biomedical Engineering Paul, Mahasweta Lau, Raymond |
format |
Article |
author |
Paul, Mahasweta Lau, Raymond |
author_sort |
Paul, Mahasweta |
title |
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery |
title_short |
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery |
title_full |
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery |
title_fullStr |
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery |
title_full_unstemmed |
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson's disease through intranasal and pulmonary delivery |
title_sort |
potentials and challenges of levodopa particle formulation for treatment of parkinson's disease through intranasal and pulmonary delivery |
publishDate |
2022 |
url |
https://hdl.handle.net/10356/160960 |
_version_ |
1743119573381545984 |